Elanco Animal Health Incorporated (NYSE:ELAN) Shares Sold by Teacher Retirement System of Texas

Teacher Retirement System of Texas lessened its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 29.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 72,272 shares of the company's stock after selling 30,470 shares during the period. Teacher Retirement System of Texas' holdings in Elanco Animal Health were worth $759,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of ELAN. Hillsdale Investment Management Inc. lifted its holdings in Elanco Animal Health by 2.1% during the 4th quarter. Hillsdale Investment Management Inc. now owns 43,300 shares of the company's stock valued at $524,000 after buying an additional 900 shares in the last quarter. Freedom Investment Management Inc. raised its holdings in shares of Elanco Animal Health by 9.1% in the 4th quarter. Freedom Investment Management Inc. now owns 20,746 shares of the company's stock valued at $251,000 after purchasing an additional 1,725 shares in the last quarter. Versant Capital Management Inc raised its holdings in shares of Elanco Animal Health by 65.9% in the 1st quarter. Versant Capital Management Inc now owns 4,382 shares of the company's stock valued at $46,000 after purchasing an additional 1,740 shares in the last quarter. Mitchell & Pahl Private Wealth LLC grew its position in shares of Elanco Animal Health by 4.0% in the 1st quarter. Mitchell & Pahl Private Wealth LLC now owns 45,489 shares of the company's stock worth $478,000 after buying an additional 1,761 shares during the last quarter. Finally, Parallel Advisors LLC grew its position in shares of Elanco Animal Health by 92.2% in the 1st quarter. Parallel Advisors LLC now owns 3,860 shares of the company's stock worth $41,000 after buying an additional 1,852 shares during the last quarter. Hedge funds and other institutional investors own 97.48% of the company's stock.

Analysts Set New Price Targets

Several analysts have weighed in on the stock. Wall Street Zen raised shares of Elanco Animal Health from a "hold" rating to a "buy" rating in a research report on Saturday, July 5th. Leerink Partners upgraded shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 target price for the company in a research note on Thursday. Stifel Nicolaus boosted their price objective on Elanco Animal Health from $16.00 to $17.00 and gave the company a "buy" rating in a research report on Wednesday, July 2nd. William Blair raised shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating in a report on Thursday, June 26th. Finally, Leerink Partnrs upgraded shares of Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a research report on Thursday. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $16.00.

Elanco Animal Health Stock Down 0.6%

Shares of NYSE ELAN traded down $0.10 during midday trading on Friday, hitting $14.87. The company's stock had a trading volume of 806,414 shares, compared to its average volume of 5,316,384. The business's fifty day simple moving average is $13.76 and its two-hundred day simple moving average is $11.77. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.71 and a quick ratio of 1.46. Elanco Animal Health Incorporated has a 1 year low of $8.02 and a 1 year high of $15.78. The firm has a market capitalization of $7.38 billion, a price-to-earnings ratio of 20.07, a price-to-earnings-growth ratio of 2.83 and a beta of 1.67.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.37 EPS for the quarter, beating the consensus estimate of $0.31 by $0.06. Elanco Animal Health had a net margin of 8.43% and a return on equity of 7.54%. The business had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. During the same quarter last year, the firm posted $0.34 earnings per share. The business's revenue for the quarter was down 1.0% compared to the same quarter last year. On average, equities analysts predict that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.